Alzamend Neuro, Inc.ALZNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank22
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
-14.33%
↓ 284% vs avg
Percentile
P22
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
7.77%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -14.33% |
| Q3 2025 | 39.28% |
| Q2 2025 | 16.68% |
| Q1 2025 | -43.62% |
| Q4 2024 | 38.52% |
| Q3 2024 | 13.38% |
| Q2 2024 | -9.73% |
| Q1 2024 | -18.39% |
| Q4 2023 | -21.99% |
| Q3 2023 | -29.99% |
| Q2 2023 | -34.64% |
| Q1 2023 | 61.11% |
| Q4 2022 | -5.19% |
| Q3 2022 | -24.96% |
| Q2 2022 | 31.41% |
| Q1 2022 | -8.23% |
| Q4 2021 | 31.94% |
| Q3 2021 | 49.90% |
| Q2 2021 | 5.21% |
| Q1 2021 | 7.09% |
| Q4 2020 | -18.43% |
| Q3 2020 | -0.79% |
| Q2 2020 | 20.15% |
| Q1 2020 | 13.47% |
| Q4 2019 | 0.00% |
| Q3 2019 | 59.97% |
| Q2 2019 | 0.00% |
| Q1 2019 | 147.87% |
| Q4 2018 | 0.00% |
| Q3 2018 | 10.63% |
| Q2 2018 | 0.00% |
| Q1 2018 | 44.76% |
| Q4 2017 | -0.00% |
| Q3 2017 | -62.45% |
| Q2 2017 | 0.00% |
| Q1 2017 | -3.41% |
| Q4 2016 | -0.00% |
| Q3 2016 | 0.00% |